Ann: Appendix 4E & Annual Report 2019, page-12

Prana used three years and most cash reserve to prove one thing. They cannot change FDA's decision. IMO, only if PBT2 was utilised to protect patients from immediate life threatening conditions, it is not possible to find any PBT2 product in the market. UQ's finding is likely a life changing opportunity for PBT2. I would not expect more than a deal between ATH and UQ. ATH needs to move on and commercialize a product ASAP. A listed company should be focusing on producing more values for its shareholders, NOT only working on what they are interested to do. A keyword in this annual report is "reset". The company is reset. The market value needs reset. Let's wait and see.